Status: Not yet recruiting
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
The purpose of this research is to investigate the activity and safety of the combination of gemcitabine plus nab-paclitaxel and sintilimab as neoadjuvant therapy in treating patients with resectable and borderline resectable pancreatic cancer. The drugs involved in this study are: * Sintilimab * Nab-paclitaxel * Gemcitabine
Participants needed: 50
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Zhongshan HospitalUpdated: Jan 22, 2025Locations: 1
Eligibility criteria
Signed informed content obtained prior to treatment [+9]
The diameter of the resectable tumor is ≤ 2 cm in imaging evaluation [+9]